{"entity":{"id":"ixabepilone","kind":"drug","name":"Ixabepilone","aka":[],"tldr":"Ixabepilone (Ixempra) is a chemotherapy infusion for breast cancer that has stopped responding to anthracyclines, taxanes and capecitabine.","summary":"Ixabepilone, a semi-synthetic epothilone, was approved by the FDA in October 2007 with capecitabine for metastatic or locally advanced breast cancer resistant to an anthracycline and a taxane (a 752-patient randomised trial showed longer progression-free survival than capecitabine alone) and as monotherapy after anthracycline, taxane and capecitabine failure. The EMA refused a marketing authorisation in 2008 on the balance of benefit and toxicity. Peripheral neuropathy is dose-limiting; the combination is contraindicated with hepatic impairment because of excess toxic deaths, and the Cremophor-based diluent requires premedication for hypersensitivity.","status":"approved","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Ixabepilone","links":[{"label":"US label (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ixabepilone"},{"label":"NCI drug page","url":"https://www.cancer.gov/about-cancer/treatment/drugs/ixabepilone"}],"tags":["nci-list"],"related":[],"cancers":["breast-hr-positive","tnbc"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":[],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":["nct00630032","nct00883116","nct00998738"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Ixempra","modality":"Epothilone B analogue (microtubule stabiliser)","mechanism":"Binds beta-tubulin and suppresses microtubule dynamics like a taxane but retains activity in cells with taxane-resistance mechanisms such as P-glycoprotein overexpression and beta-III tubulin.","approvals":[{"region":"US","year":2007,"indication":"Metastatic or locally advanced breast cancer after anthracycline and taxane (with capecitabine) or after anthracycline, taxane and capecitabine (monotherapy)"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ixabepilone/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}],"trial":[{"id":"nct00883116","kind":"trial","name":"A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer","route":"/trials/nct00883116/"},{"id":"nct00998738","kind":"trial","name":"Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer","route":"/trials/nct00998738/"},{"id":"nct00630032","kind":"trial","name":"Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer","route":"/trials/nct00630032/"}]}}